Iwilfin (eflornithine) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

| MEMBER'S LAST NAME: | | _ MEMBER'S FIRS | MEMBER'S FIRST NAME: | | |
|--|---|-----------------------------------|------------------------|---|--|
| that is important for the re | | lab data, to support | | nny additional documentatio cation request). Information | |
| | | | | | |
| MEMBER INFORMATION | ON | | | | |
| LAST NAME: | FIRST NAME | FIRST NAME: | | | |
| PHONE NUMBER: | DATE OF BIF | DATE OF BIRTH: | | | |
| STREET ADDRESS: | | | | | |
| CITY: | | STATE: | ZIP C | CODE: | |
| PATIENT INSURANCE | ID NUMBER: | | | | |
| MALE FEMALE | HEIGHT (IN/CM): | _ WEIGHT (LB/K(| G): <i>A</i> | ALLERGIES: | |
| FOLLOWING LINK: PRI PATIENT'S AUTHORIZE AUTHORIZED REPRESI | IZATION FORM WITH TH METHERAPEUTICS.COM ED REPRESENTATIVE (IF ENTATIVE'S PHONE NUI | <u>M/NOPP</u> F APPLICABLE): _ | | | |
| PRESCRIBER INFORM | IATION | FIDOT MAME | | | |
| LAST NAME: | | | FIRST NAME: | | |
| PRESCRIBER SPECIA | LTY: | EMAIL ADDR | EMAIL ADDRESS: | | |
| NPI NUMBER: | DEA NUMBE | DEA NUMBER: | | | |
| PHONE NUMBER: | FAX NUMBE | FAX NUMBER: | | | |
| STREET ADDRESS: | | | | | |
| CITY: | STATE: | STATE: ZIP CODE: | | | |
| REQUESTER (if different than prescriber): | | OFFICE CON | OFFICE CONTACT PERSON: | | |
| | | | | | |
| MEDICATION OR MED MEDICATION NAME: | ICAL DISPENSING INFO | RMATION | | | |
| _ | | | | | |
| DOSE/STRENGTH: | FREQUENCY: | LENGTH OF THERAPY/RI | EFILLS: | QUANTITY: | |
| ☐ NEW THERAPY | | RENEWAL: DATE | THERAPY | INITIATED: | |
| DURATION OF THERA | PY (SPECIFIC DATES): | | | | |

© YYYY-YYYY Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 11.1.24 CAT009



Continued on next page

Iwilfin (eflornithine) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

| MEMBER'S LAST NAME: | MEMBER'S FIRST N | NAME: |
|--|---|--------------------------------------|
| 1. HAS THE PATIENT TRIED ANY | OTHER MEDICATIONS FOR THIS | CONDITION? |
| YES (if yes, complete below) | NO | |
| MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE): | DURATION OF THERAPY (SPECIFY DATES): | RESPONSE/REASON FOR FAILURE/ALLERGY: |
| 2. LIST DIAGNOSES: | | ICD-10: |
| ☐ High-risk neuroblastoma(HRNB☐ Other diagnosis: |) ICD-10 Code(s): | |
| 3. REQUIRED CLINICAL INFORM TO SUPPORT A PRIOR AUTHOR | ATION: PLEASE PROVIDE ALL REI IZATION. | LEVANT CLINICAL INFORMATION |
| Is patient going to be using drug | in combination with a clinical trial | ? ☐ Yes ☐ No |
| Is the neuroblastoma is in remiss | sion? 🗌 Yes 🔲 No Please submit | documentation. |
| | other chemotherapy treatment in co No Please submit documentation. | ombination with |
| Has patient had previous chemor | therapy? 🗌 Yes 🔲 No Please sub | omit documentation. |
| Has patient had an autologous s documentation. | tem-cell transplant(ASCT)? | 。 |
| | onsolidation treatment with 13-cis-F Yes | |
| Are there any other comments, d information the physician feels is | liagnoses, symptoms, medications s important to this review? | tried or failed, and/or any other |
| | | |
| required information is received. | is are covered on all plans. This requ | • |
| understand that the Health Plan, in: | nation provided is true and accurate to surer, Medical Group or its designees cessary to verify the accuracy of the i | may perform a routine audit and |
| Prescriber Signature or Electron | ic I.D. Verification: | Date: |
| CONTINUE DE LA CONTIN | | |
| | documents accompanying this transr . If you are not the intended recipient | |

© YYYY-YYYY Prime Therapeutics Management LLC, a Prime Therapeutics company Prime Therapeutics Management – Commercial Clients. Revision Date: 11.1.24 CAT009



Iwilfin (eflornithine) Prior Authorization Request Form

Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

| MEMBER'S LAST NAME: | MEMBER'S FIRST NAME: | |
|----------------------------|--------------------------|--|
| | | |

disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640

MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program

Attn: CP-4201 P.O. Box 64811 St. Paul, MN 55164-0811 **Phone**: 877-228-7909

